"Zycords" – Patent GRANTED by EPO!

Concenter Biopharma is proud to announce another acceptance of the Patent covering the Second Generation of the novel anti-diabetic drug candidate – the “Zycords”.

The patent was recently granted by the European Patent Office and was validated in major European countries.

The “Zycord” compounds work through the analogous mechanisms (to the Zygosid-50 drug) and are expected to demonstrate high therapeutic potential. The investigation of their safety and efficacy will begin later this year.

The priority patent of the “Zycord” family is 12/2014 and it is being examined in numerous jurisdictions worldwide. The Claims of this Patent protect the COMPOSITION OF MATTER of the Zycords - the novel family of compounds, defined as a platform of drugs, and include their use in medicine in several modes of administration.

Intellectual Property PATENTED Seal

Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 


Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

  • LinkedIn
  • Facebook
  • Twitter


Thank you for your interest in Concenter BioPharma.

To contact us please reach us via: